Synapse - Works

Results (4640)

A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors

Meeting Abstract

Dumbrava, E. E.; Iqbal, S.; Turcotte, S.; Botta, G. P.; Schlechter, B. L.; Ku, G. Y.; Hosein, P. J.; Saibil, S.; Gavriliuc, M.; Apostolopoulou, M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: A post hoc analysis of NAPOLI 3

Meeting Abstract

Patel, A. J.; Laursen, A. A.; Cockrum, P.; Liu, Y.; Surinach, A.; Rhodes, W.; Zhang, L.; Li, J.; Maxwell, F.; Wainberg, Z. A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial

Meeting Abstract

Picozzi, V. J.; Varghese, A. M.; Oberstein, P. E.; Hidalgo, M.; Wolpin, B. M.; Lim, K. H.; McGlothlin, A.; Graves, T.; Detry, M. A.; Fitzgerald, M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3

Meeting Abstract

Abdelrahim, M.; Khan, G.; Hatoum, H.; Zervoudakis, A.; Dayyani, F.; Zhang, L.; Li, J.; Maxwell, F.; O'Reilly, E. M.; Wainberg, Z. A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

Meeting Abstract

Garrido-Laguna, I.; Wolpin, B. M.; Park, W.; Azad, N. S.; Spira, A. I.; Starodub, A.; Sommerhalder, D.; Punekar, S. R.; Herzberg, B.; Barve, M. A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Evaluating the relative treatment efficacy of CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) using unanchored indirect treatment comparisons (ITCs)

Meeting Abstract

O'Reilly, E. M.; Macarulla, T.; Dahan, L.; Borbath, I.; Cassier, P. A.; Guelfucci, F.; Ngami, A.; Pico de Coaña, Y.; Wainberg, Z. A.; Ambarkhane, S. V.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies

Meeting Abstract

Thummalapalli, R.; Darmofal, M.; Seier, K.; Khalil, D. N.; Walch, H. S.; Shia, J.; Park, W.; El Dika, I. H.; Chatila, W. K.; Schultz, N.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Obesity and biliary tract cancers: Changing epidemiology

Meeting Abstract

Al Mahmasani, L.; Chou, J. F.; Capanu, M.; Srivastava, A.; Sigel, C. S.; Alsuwailem, R.; Berger, M. F.; Khalil, D. N.; Harding, J. J.; O'Reilly, E. M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602)

Meeting Abstract

Strosberg, J. R.; Zemla, T. J.; Geyer, S. M.; Knopp, M. V.; Behr, S.; Pulsipher, S.; Acoba, J. D.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Association between immune-related adverse events and prognosis after immune checkpoint inhibitor in hepatocellular carcinoma: A meta-analysis and systematic review

Meeting Abstract

Hwang, S. Y.; Rezaee-Zavareh, M. S.; Attia, A. M.; Kaymen, E.; Tran, N. H.; Abou-Alfa, G. K.; Singal, A.; Yang, J. D.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save